All articles by Praveen Duddu

1. Deals this week: Vistin Pharma, Shenzhen Neptunus Bioengineering

   Vistin Pharma plans to raise up to Nkr300m ($38.82m) in gross proceeds through a private placement of shares of its common…
   Read More…

   23 Mar
2. M&As this week: Otsuka Pharmaceutical Factory, Shin Kowa Pharmaceutical

   Otsuka Pharmaceutical Factory has reached an agreement with Mitsui & Co to acquire a remaining 20% interest in Otsuka Pharmaceutical India…
   Read More…

   23 Mar
3. Deals and M&As this week: Zydus Cadila Healthcare, Eisai, Tabuk Pharmaceuticals Manufacturing Company

   Zydus Cadila Healthcare has signed an agreement with Medicure’s subsidiary Medicure International for the commercialisation of its ZYPITAMAG (pitavastatin magnesium) drug,…
   Read More…

   9 Mar
4. Deals this week: ExpreS2ion Biotech Holding, Arbutus Biopharma, Intrexon

   ExpreS2ion Biotech Holding, a biopharmaceutical company based in Denmark, intends for a rights offering of 2,400,403 shares at a price…
   Read More…

   19 Jan
5. Deals this week: China Meheco, Recordati, Novartis

   China Meheco intends to form a Chinese pharmaceutical joint venture (JV) through its subsidiary with a capital of CNY10m ($1.51m). To…
   Read More…

   22 Dec
6. M&As this week: Strides Pharma Asia, GlaxoSmithKline

   Strides Pharma Asia has agreed to purchase a 55% stake in South African pharmaceutical company Trinity Pharma for R55m ($4.31m)….
   Read More…

   22 Dec
7. Report: Multiple sclerosis disease-modifying therapies market to witness CAGR of 2.9%

   Sales of multiple sclerosis (MS) disease-modifying therapies (DMTs) are projected to grow from $19.1bn in 2016 to $25.3bn in 2026,…
   Read More…

   15 Dec
8. Deals this week: Revance Therapeutics, GW Pharmaceuticals, Valeant Pharmaceuticals International

   Revance Therapeutics intends to raise $175m through an underwritten public offering of the shares of its common stock. Underwriters will…
   Read More…

   8 Dec
9. M&As this week: CVS Health Corporation, NeuroSearch

   CVS Health Corporation (CVS) has agreed to acquire the entire outstanding shares of Aetna for a total consideration of $77bn….
   Read More…

   8 Dec
10. Deals this week: Eris Lifesciences, Sichuan Languang Development, Xiangxue Pharmaceutical, Navamedic

    Eris Lifesciences has reached an agreement to purchase Strides Shasun’s Indian generics business for $76.73m. Under the agreement, Eris will take…
    Read More…

    24 Nov